Abstract:CONSPECTUS: The advent of photochemical techniques has revolutionized the landscape of biology and medical sciences. Especially appealing in this context is photodynamic therapy (PDT), which is a photon-initiated treatment modality that uses cytotoxic reactive oxygen species (ROS) to kill malignant cells. In the past decade, PDT has risen to the forefront of cancer therapy. Its optical control enables noninvasive and spatiotemporal manipulation of the treatment process, and its photoactive nature allows unique patterns to avoid drug resistance to conventional chemotherapeutics. However, despite the impressive advances in this field, achieving widespread clinical adoption of PDT remains difficult. A major concern is that in the hostile tumor microenvironment, tumor cells are hypoxic, which hinders ROS generation during PDT action. To overcome this "Achilles' heel", current strategies focus primarily on the improvement of the intratumoral O2 perfusion, while clinical trials suggest that O2 enrichment may promote cancer cell proliferation and metastasis, thereby making FDA approval and clinical transformation of these paradigms challenging. In an effort to improve hypoxia photodynamic therapy (hPDT) in the clinic, we have explored "low to no O2-dependent" photochemical approaches over the years to combat hypoxia-induced resistance. In this Account, we present our contributions to this theme during the past 5 years, beginning with low O2-dependent approaches (e.g., type I superoxide radical (O2 center dot-) generator, photodynamic O2-economizer, mitochondrial respiration inhibition, cellular self-protective pathway modulation, etc.) and progressing to O2-independent strategies (e.g., autoadaptive PDT/PTT complementary therapy, O2-independent artificial photoredox catalysis in cells). These studies have attracted tremendous attention. Particularly in the pioneering work of 2018, we presented the first demonstration that the O2 center dot--mediated partial O2-recyclability mechanism can overcome PDT resistance (J. Am. Chem. Soc. 2018, 140, 14851-14859). This launched an era of renewed interest in type I PDT, resulting in a plethora of new O2 center dot- photogenerators developed by many groups around the world. Moreover, with the discovery of O2-independent photoredox reactions in living cells, artificial photoredox catalysis has emerged as a new field connecting photochemistry and biomedicine, stimulating the development of next-generation phototherapeutic tools (J. Am. Chem. Soc. 2022, 144, 163-173). Our recent work also disclosed that "photoredox catalysis in cells" might be a general mechanism of action of PDT (Proc. Natl. Acad. Sci. U.S.A. 2022, 119, e2210504119). These emergent concepts, molecular designs, photochemical mechanisms, and applications in cancer diagnosis and therapeutics, as well as pros and cons, are discussed in depth in this Account. It is expected that our contributions to date will be of general use to researchers and inspire future efforts to identify more promising hPDT approaches that better meet the clinical needs of cancer therapy.

Photodynamic Therapy: Controllable Photodynamic Therapy Implemented by Regulating Singlet Oxygen Efficiency (adv. Sci. 7/2017)

Controllable Photodynamic Therapy Implemented by Regulating Singlet Oxygen Efficiency

A New Insight into the Singlet Oxygen Mechanism for Photodynamic Therapy

Singlet Oxygen in Photodynamic Therapy

Photo‐Triggered Fluorescence Polyelectrolyte Nanoassemblies: Manipulate and Boost Singlet Oxygen in Photodynamic Therapy

Recent progress in the development of singlet oxygen carriers for enhanced photodynamic therapy

Photoswitchable Micelles for the Control of Singlet-Oxygen Generation in Photodynamic Therapies.

Protein-Activatable Diarylethene Monomer as a Smart Trigger of Noninvasive Control Over Reversible Generation of Singlet Oxygen: A Facile, Switchable, Theranostic Strategy for Photodynamic-Immunotherapy

Recent Progress in Thermally Activated Delayed Fluorescence Photosensitizers for Photodynamic Therapy

Deciphering Oxygen‐Independent Augmented Photodynamic Oncotherapy by Facilitating the Separation of Electron‐Hole Pairs

New Cyclometalated Transition-Metal Based Photosensitizers for Singlet Oxygen Generation and Photodynamic Therapy

Recent Advances in Thermally Activated Delayed Fluorescent Materials in Type II Photodynamic Therapy

A Phototheranostic Strategy to Continuously Deliver Singlet Oxygen in the Dark and Hypoxic Tumor Microenvironment

Recent Advances in Activatable Organic Photosensitizers for Specific Photodynamic Therapy

Strategies to construct efficient singlet oxygen-generating photosensitizers

Revealing Excited-State Dynamics of Type I Zinc Phthalocyanine Photosensitizer for Photodynamic Therapy

Programmable Singlet Oxygen Battery for Automated Photodynamic Therapy Enabled by Pyridone-Pyridine Tautomer Engineering

Tuning singlet oxygen generation with caged organic photosensitizers

From Low to No O2-Dependent Hypoxia Photodynamic Therapy (hPDT): A New Perspective

Photosensitizer-Singlet Oxygen Sensor Conjugated Silica Nanoparticles for Photodynamic Therapy and Bioimaging

Phototherapy: Targeting‐Triggered Porphysome Nanostructure Disruption for Activatable Photodynamic Therapy (adv. Healthcare Mater. 8/2014)